Integer Holdings AI Stock Analysis
Want to see ITGR full AI Analyst Report?
Integer Holdings (ITGR) AI Stock Analysis
Integer Holdings
(NYSE:ITGR)
The score is driven primarily by mid-tier financial performance: decent margins and manageable leverage, but a sharp TTM revenue decline and operating margin compression are meaningful near-term risks. Technicals are moderately supportive with price above longer-term averages and positive MACD. Valuation is a headwind due to a high P/E and no dividend yield provided. Corporate events are a positive offset given the advanced, shareholder-approved take-private transaction.
Integer Holdings Key Performance Indicators (KPIs)
Revenue by SegmentBreaks down sales across the company’s business units or product lines to show which areas drive growth and profits. Highlights dependence on any single segment or customer, differences in margins across lines, and where future expansion or downside risk is likely to come from — essential for judging Integer’s diversification, stability of cash flow, and how acquisitions or shifts in end markets will affect results.
Cardio & Vascular has been the primary growth engine and remains central to Integer’s trajectory, but management warns of temporary EP normalization that could pause that momentum; CRM&N looks steady but is flattening, while Other Markets and the non‑medical electrochem line have been effectively removed from the growth mix (portfolio exits/reclassifications), increasing reliance on core med‑tech sales. That concentration helps explain rising top‑line resilience alongside the company’s margin and cash‑flow pressures, motivating cost actions, buybacks and a board‑led strategic review.
Integer Holdings (ITGR) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $4.31B
- Dividend Yield
- ―
- Average Volume (3M)
- 790.83K
- Price to Earnings (P/E)
- 42.2
- Beta (1Y)
- 0.42
- Revenue Growth
- -0.33%
- EPS Growth
- 20.67%
- Country
- US
- Employees
- 11,000
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Integer Holdings Business Overview & Revenue Model
Company Description
Integer Holdings Corporation functions as a global leader in outsourced medical device manufacturing, maintaining operations across the United States, Puerto Rico, Costa Rica, and other international regions. The company organizes its business into t...
How the Company Makes Money
Integer primarily makes money by providing contract development and manufacturing services to medical device OEMs, earning revenue from producing and supplying components, subassemblies, and finished/finished-ready medical devices under customer cont...
Integer Holdings Earnings Call Summary
The call conveyed a mixed picture: a modest top-line improvement in Q1 (reported +0.5%, organic +1.3%) and several strategic positives (share buybacks, lower interest expense, targeted cost actions, pipeline strength and a Board-initiated strategic review) were offset by meaningful near-term profitability pressures (adjusted operating income down 14%, margin contraction of 230 bps), weaker cash flow in Q1, and a downward revision to full-year 2026 revenue and profit guidance. Management characterizes the demand softness—primarily in electrophysiology—as temporary normalization and emphasized actions to protect long-term growth, but the guidance cuts and margin contraction represent notable near-term headwinds.
Q1-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Integer updated its 2026 guidance with full‑year reported sales now expected at $1.805–$1.835 billion (down 1%–3% YoY) and organic sales flat to down 1% (including a ~3%–4% headwind from three new products; organic growth excluding those products ~3%–4%); inorganic decline ~1% (Portable Medical exit); C&V expected flat to down low‑single digits, CRM&N flat to up low‑single digits, and other markets down ~$34M–$36M. Profitability outlook: adjusted EBITDA $375M–$399M (down 1%–7%), adjusted operating income $285M–$305M (down 5%–11%) with sequential margin improvement expected (Q2 operating margin +80–140 bps and continuing improvement through 2026), adjusted net income $200M–$220M (down 3%–11%) and adjusted EPS $5.83–$6.40 (flat to down 9%). Cash/debt targets: cash flow from operations $185M–$205M (≈$15M lower at midpoint), CapEx $95M–$105M (~5%–6% of sales), free cash flow $85M–$105M, year‑end net total debt $1.185B–$1.205B and leverage expected in the 2.5x–3.5x trailing‑4Q adjusted EBITDA target range (Q1 net total debt $1.264B, leverage 3.2x). Q1 actuals and drivers: sales $440M (+0.5% reported, +1.3% organic), adjusted EBITDA $85M (‑7%), adjusted operating margin 13.9% (‑230 bps), adjusted net income $41M (‑10%), adjusted EPS $1.20 (‑8%), cash from ops $25M, CapEx $24M, free cash flow $1M; interest expense was $4M lower (helping EPS by ~$0.10), and share repurchases of $50M in Q4 ’25 (~700k shares) and $50M in Q1 ’26 (~600k shares) reduced weighted shares ~2% (adding ~$0.02 to EPS).
Integer Holdings Financial Statement Overview
Summary
Financials are solid but uneven. Revenue grew over 2021–2025, yet the TTM shows a sharp reported revenue decline and operating margin compression versus the 2024 peak (EBIT margin ~13.0% in 2024 vs ~9.5% TTM). Profitability is still decent (TTM net margin ~7.0%, EBITDA margin ~17.0%) and the balance sheet is reasonably leveraged (debt ~0.79x equity) with acceptable ROE (~7.4%). Free cash flow is positive (~$149M TTM) but conversion is mixed (OCF ~0.95x net income; FCF ~55% of net income). Segment KPIs indicate growing reliance on Cardio & Vascular while Other Markets deteriorated, which adds concentration risk.
Income Statement
62PositiveBalance Sheet
66PositiveCash Flow
58Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.82B | 1.85B | 1.72B | 1.56B | 1.33B | 1.22B |
| Gross Profit | 430.19M | 425.81M | 461.18M | 411.52M | 346.65M | 336.97M |
| EBITDA | 286.19M | 298.38M | 334.26M | 277.56M | 222.84M | 224.43M |
| Net Income | 103.70M | 102.76M | 119.90M | 90.65M | 66.38M | 96.81M |
Balance Sheet | ||||||
| Total Assets | 3.39B | 3.41B | 3.08B | 2.94B | 2.79B | 2.58B |
| Cash, Cash Equivalents and Short-Term Investments | 14.13M | 17.16M | 46.54M | 23.67M | 24.27M | 17.89M |
| Total Debt | 1.34B | 1.40B | 1.10B | 1.05B | 1.01B | 905.81M |
| Total Liabilities | 1.67B | 1.66B | 1.46B | 1.42B | 1.38B | 1.23B |
| Stockholders Equity | 1.73B | 1.75B | 1.62B | 1.52B | 1.42B | 1.35B |
Cash Flow | ||||||
| Free Cash Flow | 81.82M | 105.12M | 99.85M | 60.27M | 41.65M | 103.20M |
| Operating Cash Flow | 176.48M | 196.15M | 205.21M | 180.21M | 116.38M | 156.67M |
| Investing Cash Flow | -116.57M | -270.73M | -195.41M | -163.37M | -200.42M | -271.00M |
| Financing Cash Flow | -103.90M | 43.56M | 13.32M | -18.01M | 92.48M | 81.99M |
Integer Holdings Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ITGR, the sentiment is Positive. The current price of 126.70 is above the 20-day moving average (MA) of 126.61, above the 50-day MA of 126.47, and above the 200-day MA of 102.84, indicating a bullish trend. The MACD of 0.14 indicates Positive momentum. The RSI at 58.88 is Neutral, neither overbought nor oversold. The STOCH value of 47.03 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ITGR.
Integer Holdings Risk Analysis
Integer Holdings disclosed 43 risk factors in its most recent earnings report. Integer Holdings reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksInteger Holdings Peers Comparison
Overall Rating
UFPT81Outperform
LIVN77Outperform
HAE71Outperform
ITGR63Neutral
NSYS62Neutral
IART44Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 81Outperform | $2.36B | 30.81 | 16.90% | ― | 8.62% | 13.50% | |
| 77Outperform | $5.03B | 25.51 | 15.35% | ― | 11.71% | ― | |
| 71Outperform | $5.60B | 54.16 | 12.07% | ― | 4.11% | -34.22% | |
| 63Neutral | $4.31B | 42.23 | 6.02% | ― | -0.33% | 20.67% | |
| 62Neutral | $30.89M | 16.64 | 5.14% | ― | 9.04% | ― | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 44Neutral | $1.12B | 85.82 | 1.24% | ― | 0.84% | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| ITGR | Integer Holdings | 126.70 | 59.60 | 88.82% | |
| HAE | Haemonetics | 122.94 | 48.62 | 65.42% | |
| IART | Integra Lifesciences | 14.40 | 2.67 | 22.76% | |
| NSYS | Nortech | 10.78 | 3.74 | 53.12% | |
| UFPT | Ufp Technologies | 305.06 | 82.24 | 36.91% | |
| LIVN | LivaNova PLC | 91.32 | 37.68 | 70.25% |
Integer Holdings Corporate Events
Integer Holdings shareholders overwhelmingly approve KKR acquisition
PositiveOn October 21, 2026, Integer Holdings Corporation stockholders met at a special meeting to vote on proposals tied to a planned merger with Armstrong Parent, Inc., an affiliate of investment funds managed by Kohlberg Kravis Roberts & Co. L.P. Sharehol...
Integer Holdings Issues Forward-Looking Strategic Disclosure Statement
NeutralInteger Holdings issued a brief communication referencing conditions or developments that may occur in the future and the timing of such matters, without providing specific operational or financial details. The statement suggests the company is addre...
Integer Holdings Opens Convertible Notes Conversion Window
NeutralOn October 2, 2026, Integer Holdings Corporation announced that its 2.125% Convertible Senior Notes due 2028 became convertible at the option of holders for the calendar quarter beginning October 1 and ending December 31, 2026. The Notes can be conve...
Integer Holdings Advances Toward KKR Acquisition Completion
PositiveInteger Holdings Corporation, a major medical device contract developer and manufacturer serving cardio and vascular, neuromodulation and cardiac rhythm management markets, operates globally under brands such as Greatbatch Medical and Lake Region Med...
KKR to Take Integer Holdings Private in Buyout
PositiveOn August 2, 2026, Integer Holdings Corporation agreed to be acquired by Armstrong Parent, Inc., an affiliate of funds managed by Kohlberg Kravis Roberts & Co. L.P., in a cash merger that will take the company private at $127 per share. The transacti...
KKR to Take Integer Holdings Private in Merger
PositiveOn August 3, 2026, Integer Holdings agreed to be acquired by an affiliate of KKR in an all-cash merger valuing the company at about $5.7 billion, with shareholders set to receive $127 per share, a significant premium to pre-review trading levels. The...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 29, 2026
